Kelly, D. F., M. D. Snape, E. A. Cutterbuck, S. Green, C. Snowden, L. Diggle, L. M. Yu, A. Borkowski, E. R. Moxon, and A. J. Pollard. 2006. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory b cells. Blood 108(8):2642-2647.

Kuhns, D. M., P. Kisner, M. P. Williams, and P. L. Moorman. 1938. The control of meningococci meningitis epidemics by active immunization with meningococcus soluble toxin further studies. Journal of the American Medical Association 110:484-487.

Laribiere, A., G. Miremont-Salame, H. Reyre, A. Abouelfath, L. Liege, N. Moore, and F. Haramburu. 2005. Surveillance of adverse effects during a vaccination campaign against meningitis C. European Journal of Clinical Pharmacology 61(12):907-911.

Makela, P. H., H. Peltola, H. Kayhty, H. Jousimies, O. Pettay, E. Ruoslahti, A. Sivonen, and O. V. Renkonen. 1977. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type B: A field trial in Finland. Journal of Infectious Diseases 136(Suppl.):S43-S50.

Miller, M. A., P. Millikin, P. S. Griffin, R. A. Sexton, and M. Yousuf. 1979. Neisseria meningitidis urethritis—case-report. Journal of the American Medical Association 242(15): 1656-1657.

Novartis Vaccines and Diagnostics, Inc. 2010. Menveo [package insert]. Cambridge, MA: Novartis Vaccines and Diagnostics, Inc.

Peng, M. M., and H. Jick. 2004. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Archives of Internal Medicine 164(3):317-319.

Pritchard, J., R. Mukherjee, and R. A. C. Hughes. 2002. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. Journal of Neurology, Neurosurgery, and Psychiatry 73(3):348-349.

Py, M. O., and C. Andre. 1997. Acute disseminated encephalomyelitis: Association with meningococcal A and C vaccine. Case report [in Portuguese]. Arquivos de Neuro-Psiquiatria 55(3B):632-635.

Racoosin, J. A., C. G. Whitney, C. S. Conover, and P. S. Diaz. 1998. Serogroup Y meningococcal disease in Chicago, 1991-1997. Journal of the American Medical Association 280(24):2094-2098.

Robbins, J. B., R. Schneerson, P. Anderson, and D. H. Smith. 1996. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type B: Impact on public health and implications for other polysaccharide-based vaccines. Journal of the American Medical Association 276(14):1181-1185.

Rosenstein, N. E., B. A. Perkins, D. S. Stephens, L. Lefkowitz, M. L. Cartter, R. Danila, P. Cieslak, K. A. Shutt, T. Popovic, A. Schuchat, L. H. Harrison, A. L. Reingold, and S. Active Bacterial Core. 1999. The changing epidemiology of meningococcal disease in the United States 1992-1996. Journal of Infectious Diseases 180(6):1894-1901.

Sanofi Pasteur, Inc. 2009. Menomune-A/C/Y/W-135 [package insert]. Swiftwater, PA: Sanofi Pasteur, Inc.

Sanofi Pasteur, Inc. 2011. Menectra [package insert]. Swiftwater, PA: Sanofi Pasteur, Inc.

Schaad, U. B. 1980. Arthritis in disease due to Neisseria meningitidis. Reviews of Infectious Diseases 2(6):880-888.

Scherp, H. W., and G. Rake. 1945. Studies on meningococcal infection. 13. Correlation between antipolysaccharide and the antibody which protects mice against infection with type-I meningococci. Journal of Experimental Medicine 81(1):85-92.

Sophian, A., and J. Black. 1912. Prophylactic vaccination against epidemic meningitis. Journal of the American Medical Association 59:527-532.

Underwood, E. A. 1940. Recent knowledge of the incidence and control of cerebrospinal fever. British Medical Journal 1940:757-763.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement